Actavia Life Sciences

Actavia Life Sciences is a pre-clinical stage biotechnology company focused on developing next-generation therapies for difficult-to-treat cancers. The company's primary focus is on the development of small molecule inhibitors targeting Casein kinase 1 alpha (CK1α) and the YAP/TAZ transcriptional coactivators, which play critical roles in cancer cell survival and resistance. Their lead programs aim to address high unmet needs in hematological malignancies like acute myeloid leukemia and various solid tumors. By leveraging its proprietary platform, Actavia seeks to disrupt oncogenic signaling pathways that are often bypassed by current standard-of-care treatments.